Company Overview

Update
Status:
Acquired by Actelion Pharmaceuticals
Founded:
2002
Headquarters:
Malvern, PA
Funding:
$25M
Categories:
Biotechnology
Description:
Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.

Detailed Description

Update

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Current Team (11)

Update

Board Members and Advisors (4)

Update

Investors (8)

Update

Offices/Locations (1)

Update
  • Office

    101 Lindenwood Drive

    Suite 400

    Malvern, PA 19355

    USA

Images (1)

Update
  • 8243f38eb635c477bc27463f1c1b2575